Literature DB >> 27605583

The Gomez' equations and renal hemodynamic function in kidney disease research.

Petter Bjornstad1, Marko Škrtić2, Yuliya Lytvyn3, David M Maahs4, Richard J Johnson5, David Z I Cherney6.   

Abstract

Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease. A major challenge in preventing DKD is the difficulty in identifying high-risk patients at an early, pre-clinical stage. Albuminuria and eGFR as measures of renal function in DKD research and clinical practice are limited by regression of one-third of patients with microalbuminuria to normoalbuminuria and eGFR is biased and imprecise in the normal-elevated range. Moreover, existing methods that are used to assess renal function do not give detailed insight into the location of the renal hemodynamic effects of pharmacological agents at the segmental level. To gain additional information about the intrarenal circulation in-vivo in humans, mathematical equations were developed by Gomez et al in the 1950s. These equations used measurements of GFR, renal blood flow (RBF), effective renal plasma flow (ERPF), renal vascular resistance (RVR), hematocrit and serum protein to calculate afferent and efferent arteriolar resistances, glomerular hydrostatic pressure and filtration pressure. Although indirect and based on physiological assumptions, these techniques have the potential to improve researchers' ability to identify early pre-clinical changes in renal hemodynamic function in patients with a variety of conditions including DKD, thereby offering tremendous potential in mechanistic human research studies. In this review, we focus on the application of Gomez' equations and summarize the potential and limitations of this technique in DKD research. We also summarize illustrative data derived from Gomez' equations in patients with type 1 (T1D) and type 2 diabetes (T2D) and hypertension.
Copyright © 2016, American Journal of Physiology-Renal Physiology.

Entities:  

Keywords:  Gomez' equations; diabetic kidney disease; glomerular filtration rate; renal blood flow; renal hemodynamics

Year:  2016        PMID: 27605583      PMCID: PMC6347069          DOI: 10.1152/ajprenal.00415.2016

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  16 in total

Review 1.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Authors:  Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles
Journal:  J Am Soc Nephrol       Date:  2017-01-31       Impact factor: 10.121

2.  Kidney Function Can Predict Pregnancy Outcomes.

Authors:  Petter Bjornstad; David Z I Cherney
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-13       Impact factor: 8.237

3.  Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.

Authors:  Harindra Rajasekeran; Heather N Reich; Michelle A Hladunewich; Daniel Cattran; Julie A Lovshin; Yuliya Lytvyn; Petter Bjornstad; Vesta Lai; Josephine Tse; Leslie Cham; Syamantak Majumder; Bridgit B Bowskill; M Golam Kabir; Suzanne L Advani; Ian W Gibson; Manish M Sood; Andrew Advani; David Z I Cherney
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-15

4.  Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes.

Authors:  Petter Bjornstad; Julie A Lovshin; Yuliya Lytvyn; Genevieve Boulet; Leif E Lovblom; Omar N Alhuzaim; Mohammed A Farooqi; Vesta Lai; Josephine Tse; Leslie Cham; Andrej Orszag; Daniel Scarr; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Bruce A Perkins; David Z I Cherney
Journal:  Diabetes Care       Date:  2018-02-02       Impact factor: 19.112

5.  Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes.

Authors:  Julie A Lovshin; Yuliya Lytvyn; Leif E Lovblom; Alexandra Katz; Geneviève Boulet; Petter Bjornstad; Vesta Lai; Leslie Cham; Josephine Tse; Andrej Orszag; Hillary A Keenan; Narinder Paul; Vera Bril; David T Wong; Kylen D McReelis; Michael H Brent; Bruce A Perkins; David Z I Cherney
Journal:  Diabetes Care       Date:  2018-12-06       Impact factor: 19.112

6.  Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Julie A Lovshin; Genevieve Boulet; Mohammed A Farooqi; Vesta Lai; Josephine Tse; Leslie Cham; Leif E Lovblom; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Andrew Advani; Etienne Sochett; Bruce A Perkins; David Z I Cherney
Journal:  Am J Kidney Dis       Date:  2019-02-22       Impact factor: 8.860

7.  Influence of sex on hyperfiltration in patients with uncomplicated type 1 diabetes.

Authors:  Marko Škrtić; Yuliya Lytvyn; Petter Bjornstad; Heather N Reich; James W Scholey; Paul Yip; Etienne B Sochett; Bruce Perkins; David Z I Cherney
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-28

Review 8.  Renal Hyperfiltration in Adolescents with Type 2 Diabetes: Physiology, Sex Differences, and Implications for Diabetic Kidney Disease.

Authors:  Petter Bjornstad; David Z Cherney
Journal:  Curr Diab Rep       Date:  2018-03-19       Impact factor: 4.810

9.  Estimation of Intraglomerular Pressure Using Invasive Renal Arterial Pressure and Flow Velocity Measurements in Humans.

Authors:  Didier Collard; Peter M van Brussel; Lennart van de Velde; Gilbert W M Wijntjens; Berend E Westerhof; John M Karemaker; Jan J Piek; Jim A Reekers; Liffert Vogt; Robbert J de Winter; Bert-Jan H van den Born
Journal:  J Am Soc Nephrol       Date:  2020-06-16       Impact factor: 10.121

10.  Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease.

Authors:  Federica Piani; Trenton Reinicke; Yuliya Lytvyn; Isabella Melena; Leif E Lovblom; Vesta Lai; Josephine Tse; Leslie Cham; Andrej Orszag; Bruce A Perkins; David Z I Cherney; Petter Bjornstad
Journal:  J Diabetes Complications       Date:  2020-11-26       Impact factor: 2.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.